Loading…
← CockpitCompetitor Analysis › REC.MI Recordati S.p.A.Open in the cockpit ↗

Recordati S.p.A.REC.MICompetitor analysis, valuation and peers

Italy · EUR·Health Care›Pharmaceuticals: Major

Italian specialty pharma maker of branded drugs for rare diseases and primary-care therapeutic areas.

≈ A smaller, Italian Jazz PharmaceuticalsMomentum neutral 55
Mkt cap
$12.0B
US dollars, full cap
Free float
48%
of shares outstanding
$/day
$35.2M
20-day average traded
Fwd P/E
16.6×
forward earnings
ROIC−WACC
+8.0 pp
WACC 6.9%
Hurdle
-11 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · EUR€52.80
1D-0.1%
1W+0.7%
1M-0.4%
3M-0.1%
6M+2.9%
YTD+8.8%
1Y+5.2%
ATR %0.5%
52w lowhigh1.9% off high

What Recordati does

Italian specialty pharma maker of branded drugs for rare diseases and primary-care therapeutic areas.

Sells prescription drugs through its own sales forces in Europe and other regions, with rare-disease drugs priced high for small patient groups and older primary-care brands providing a steady base. Growth has relied partly on buying drug rights and companies, rather than only on in-house research.

In one line: A smaller, Italian Jazz Pharmaceuticals.

Products and services

  • Rare disease drugs
  • Primary care branded drugs
  • Consumer healthcare

Customers

  • Hospitals/specialist physicians
  • Pharmacies
  • Healthcare payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Specialty/branded pharma
  • Rare disease + primary care drugs

What could go right

  • Orphan drug launches/geographic expansion
  • Bolt-on acquisitions

What could go wrong

  • Patent cliffs on branded generics
  • Drug pricing pressure in Europe

Moat: narrow (IP / patents, regulatory licence, distribution). Orphan-drug exclusivity and a long-standing branded sales network across Europe/Turkey.

Headquarters: Milan, Italy · Founded: 1926 · Employees: 4,693

Named competitors

Recordati at a glance

Size Recordati (REC.MI) is an Italy Health Care company (Pharmaceuticals: Major) with a market value of $12.0B, the 23rd largest of 121 Italy companies the cockpit tracks. Shares closed at €52.80 on 18 Nov 2026.

Performance Over six months the shares gained 2.9%, against +8.3% for the median peer and +3.1% for the Italy market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 8.3% over the last twelve months (peer median +14.6%); the operating margin is 30.2% (peer median 20.6%).

Valuation It trades at 16.6× forward earnings against a peer median of 31.9× (3rd cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 8.0 points above its cost of capital (6.9% WACC).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

9510010511021 May 202621 Aug 202618 Nov 2026Peer median 109REC.MI 103
Six months, rebased to 100: Recordati against the median of its 20 peers (local-currency closes).

Recordati financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€2.77B€2.62B€2.34B€2.08B€1.85B
Revenue growth—+12%+12%+12%—
Gross profit€1.97B€1.79B€1.60B€1.42B€1.29B
EBITDA€1.05B€926M€827M€708M€620M
Net income€524M€444M€417M€389M€312M
Free cash flow€620M€557M€533M€456M€438M
Capital expenditure€148M€85.1M€851M€383M€96.3M
Total debt€2.20B€2.47B€2.48B€1.81B€1.72B

Quarterly statements and history in the cockpit →

Recordati competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%+20%1177600436MANKINDDRREDDYZYDUSLIFERGEN6990LAURUSLABSTGTX300759IPNSYRE6885060005386446MDGLHLUN-AORNAVSOBIREC.MI6-month return →1-month return →
Up and to the right = strong over both horizons. Recordati is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×500×1,000×1177600436MANKINDDRREDDYRGEN6990TGTX6446MDGLORNAVREC.MIRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Recordati is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%+400%0%200%400%1177600436RGENTGTXIPN6446REC.MIGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Recordati is the large dot.

Recordati competitors and peer comparison

Head to head with its named competitors (REC.MI vs JAZZ vs IPN.PA vs SOBI.ST)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Recordati REC.MI$12.0B+3%+8%30%16.6×1.1%
Jazz Pharmaceuticals Public JAZZ$15.9B+4%+13%25%9.3×-2.8%
Ipsen IPN.PA$14.8B+1%+14%30%10.8×-6.7%
Swedish Orphan Biovitrum SOBI.ST$16.1B+6%+15%30%24.1×-2.1%

How Recordati compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Recordati against its 20 peers (data as of 18 Nov 2026)
MeasureREC.MIPeer medianRank in peer set
1-month return-0.4%+6.7%5th lowest of 21
6-month return+2.9%+8.3%6th lowest of 21
Distance from 52-week high-1.9%-6.8%2nd highest of 21
Revenue growth (TTM)+8.3%+14.6%4th lowest of 20
Operating margin30.2%20.6%4th highest of 20
Forward P/E16.6×31.9×3rd cheapest of 18
Growth the price implies (Req g, 7 yrs)1.1%23.7%8th least demanding of 16
Growth delivered (Del g)+12.6%+12.1%7th highest of 16
Hurdle (Req g minus delivered)-11.4 pp-11.0 pp8th least demanding of 16
ROIC minus cost of capital+8.0 pp+3.3 pp7th highest of 19
EV / EBITDA12.0×18.2×5th cheapest of 14
Net debt / EBITDA1.6×0.6×most indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%40.7×24.9%+6.8%
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%44.4×28.6%+18.1%
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Repligen RGENUnited States$11.0B+55%+14%9%71.0×56.9%+15.0%
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
TG Therapeutics TGTXUnited States$9.99B+66%+69%21%25.2×43.0%+426.7%
Pharmaron Beijing 300759.SZChina$9.90B+52%+18%14%36.8×n/an/a
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%18.3×-0.2%+4.7%
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%81.5×n/an/a
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%n/a-6.6%+6.6%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%24.1×-2.1%+13.1%

Questions

Who are Recordati's main competitors?
Named competitors: Jazz Pharmaceuticals (JAZZ), Ipsen (IPN.PA), Swedish Orphan Biovitrum (SOBI.ST), Chiesi Farmaceutici (private or unlisted). The cockpit's measured peer set (industry) also includes Sbp (1177.HK), Zhangzhou Pientzehuang Pharmaceutical (600436.SS), Mankind Pharma (MANKIND.NS), Dr. Reddy's Laboratories (DRREDDY.NS), Zydus Lifesciences (ZYDUSLIFE.NS), Repligen (RGEN).
Is Recordati expensive compared with its peers?
On forward p/e it trades at 16.6× against a peer median of 31.9×, 3rd cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has Recordati stock performed?
Over six months to 18 Nov 2026 the shares returned +2.9% against +8.3% for the median peer; over one year +5.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.